We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

CSF Biomarker Flags Parkinson's Pathology Much Earlier

By LabMedica International staff writers
Posted on 16 Mar 2021
Print article
Image: In-vitro misfolded α-synuclein amplification by real-time quaking-induced conversion (Photo courtesy of University of Edinburgh).
Image: In-vitro misfolded α-synuclein amplification by real-time quaking-induced conversion (Photo courtesy of University of Edinburgh).
Isolated rapid-eye-movement (REM) sleep behavior disorder (IRBD) can be part of the prodromal stage of the α-synucleinopathies Parkinson's disease and dementia with Lewy bodies years before clinical symptoms appear.

Real-time quaking-induced conversion (RT-QuIC) analysis of cerebrospinal fluid (CSF) has high sensitivity and specificity for the detection of misfolded α-synuclein in patients with Parkinson's disease and dementia with Lewy bodies.

An international team of Neuroscientists working with the University of Edinburgh (Edinburgh, UK) obtained CSF samples by lumbar puncture from patients with video polysomnography-confirmed IRBD recruited at a specialized sleep disorders center in Barcelona, Spain, and from controls free of neurological disease. There were 52 patients with IRBD and 40 healthy controls matched for age, sex and duration of follow-up underwent lumbar puncture between March 23, 2008, and July 16, 2017. CSF samples were stored until analyzed using RT-QuIC.

The team reported that during follow-up, 32 patients (62%) were diagnosed with Parkinson's disease or dementia with Lewy bodies a mean 3.4 years after lumbar puncture, of whom 31 (97%) were α-synuclein positive at baseline. Specifically, 16 people developed Parkinson's (15 of whom were positive for CSF α -synuclein), and 16 developed dementia with Lewy bodies (all were positive for CSF α-synuclein). CSF α-synuclein RT-¬QuIC was positive in 47 (90%) of 52 patients and in four (10%) of 40 healthy controls, resulting in a sensitivity of 90.4% (95% CI 79.4–95.8) and a specificity of 90.0% (95% CI 76.9–96.0).

The average interval for people who were alpha-synuclein positive at baseline to convert to clinically defined Parkinson's or dementia with Lewy bodies was 3.2 years. Patients with IRBD who were α-synuclein negative had lower risk for developing Parkinson's disease or dementia with Lewy bodies at 2, 4, 6, 8, and 10 years of follow-up than patients with IRBD who were α-synuclein positive. During follow-up, none of the controls developed an α-synucleinopathy.

Alison Green, PhD, a Reader in Biochemistry and a senior author of the study, said, “The detection of pathological α-synuclein preceded the development of clinical symptoms by a mean of 3.2 years, with a range of 6 months to 9 years. This is the first step towards having a reliable biomarker for early, pre-symptomatic disease which will enable therapeutic interventions, including potential neuroprotective treatments, to start in a timelier manner.”

The authors concluded that in patients with IRBD, RT-QuIC detects misfolded α-synuclein in the CSF with both sensitivity and specificity of 90%, and α-synuclein positivity was associated with increased risk of subsequent diagnosis of Parkinson's disease or dementia with Lewy bodies. Detection of α-synuclein in the CSF represents a potential prodromal marker of Parkinson's disease and dementia with Lewy bodies. The study was published on March 1, 2021 in the journal Lancet Neurology.


Related Links:
University of Edinburgh

New
Gold Supplier
TRANSPORT MEDIUM
TRANSPORT MEDIUM-2
New
COVID-19 Rapid Test Cassette
RightSignCOVID-19 Rapid Test Cassette
New
Immunofluorescence Quantitative Analyzer
Quant-fluo 800
New
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.